Auro Vaccines

Focus: Auro Vaccines is a biotechnology company headquartered in Pearl River, NY, focused on developing vaccines for high-threat infectious diseases including Ebola, Nipah, and HIV.

Infectious Diseases Vaccines

Profile data last refreshed 15h ago · AI intelligence enriched 2w ago

Open Jobs

About Auro Vaccines

AI assessmentNot Hiring

No open roles listed right now. Follow Auro Vaccines to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

HIV-MAG Vaccine

HIV Infection

Phase 1

Clinical Trials (1)

NCT01496989Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers

Phase 1

Help build intelligence for Auro Vaccines

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage pipeline focused on high-impact global health threats (Ebola, Nipah, HIV) with significant unmet medical need
Ground-floor opportunity at a vaccine-focused biotech with potential for meaningful scientific contribution to infectious disease prevention
Potential for equity upside if pipeline advances and company achieves clinical milestones or partnership deals

Watch Out For

All four programs are in Phase 1 with no Phase 2/3 advancement yet—early clinical failure risk is substantial
Zero active job openings and missing data on funding, employee count, and financial health suggest either dormancy or limited near-term hiring
No commercialized products, published research output, or recent news in public record raises visibility and track record concerns

Generated by Claude from Auro Vaccines's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

FLSC Vaccine

HIV Infection

Phase 1

Clinical Trials (1)

NCT02756208A Safety and Immunogenicity Trial of IHV01

Phase 1

rVSV

HIV

Phase 1

Clinical Trials (1)

NCT01859325Therapeutic Vaccine for HIV

Phase 1

Ebola Zaire Vaccine

Ebola Virus Disease

Phase 1

Clinical Trials (1)

NCT02718469Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults

Phase 1

Nipah Virus Vaccine

Nipah Virus Infection

Phase 1

Clinical Trials (1)

NCT04199169Safety and Immunogenicity of a Nipah Virus Vaccine

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 5 clinical trials

Top TAs: Infectious Diseases, Vaccines

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Infectious Diseases

3 pipeline

Vaccines

1 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles